Genzyme’s Synvisc-One
This article was originally published in The Gray Sheet
Executive Summary
Genzyme expects approval of its next-generation Synvisc osteoarthritis treatment for the knee to be delayed in the United States until at least the second half of 2008, since FDA has requested additional analyses and data on the PMA application, the firm says Nov. 13.Synvisc-One is a single-treatment version expected to provide up to six months of pain relief. The current version of Synvisc is delivered in three administrations at one-week intervals (1"The Gray Sheet" Jan. 1, 2007, p. 9). The firm is waiting for a CE mark on the product in Europe, and if approved there, will pursue marketing approval in Asia and Latin America
You may also be interested in...
FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy
FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy
CMS Bends Knee Injection Code Policy Under Pressure From Genzyme
CMS reversed course with a Dec. 14 decision to pay for viscosupplement injections for osteoarthritic knees under four distinct codes in 2007 following persistent pressure from the products' manufacturers
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.